DE69937964D1 - Transportreagentien - Google Patents

Transportreagentien

Info

Publication number
DE69937964D1
DE69937964D1 DE69937964T DE69937964T DE69937964D1 DE 69937964 D1 DE69937964 D1 DE 69937964D1 DE 69937964 T DE69937964 T DE 69937964T DE 69937964 T DE69937964 T DE 69937964T DE 69937964 D1 DE69937964 D1 DE 69937964D1
Authority
DE
Germany
Prior art keywords
transportreagentien
substances
cells
disclosed
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69937964T
Other languages
English (en)
Other versions
DE69937964T2 (de
Inventor
Yongliang Chu
Malek Masoud
Gulilat Gebeyehu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Invitrogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invitrogen Corp filed Critical Invitrogen Corp
Application granted granted Critical
Publication of DE69937964D1 publication Critical patent/DE69937964D1/de
Publication of DE69937964T2 publication Critical patent/DE69937964T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C211/21—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/64—Quaternary ammonium compounds having quaternised nitrogen atoms bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
DE69937964T 1998-11-12 1999-11-12 Transportreagentien Expired - Lifetime DE69937964T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10811798P 1998-11-12 1998-11-12
US108117P 1998-11-12
PCT/US1999/026825 WO2000027795A1 (en) 1998-11-12 1999-11-12 Transfection reagents

Publications (2)

Publication Number Publication Date
DE69937964D1 true DE69937964D1 (de) 2008-02-21
DE69937964T2 DE69937964T2 (de) 2009-01-02

Family

ID=22320415

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69937964T Expired - Lifetime DE69937964T2 (de) 1998-11-12 1999-11-12 Transportreagentien

Country Status (13)

Country Link
US (12) US7166745B1 (de)
EP (3) EP2298728A1 (de)
JP (2) JP4854853B2 (de)
AT (1) ATE383331T1 (de)
AU (1) AU772847B2 (de)
CA (1) CA2350882C (de)
CY (1) CY1107895T1 (de)
DE (1) DE69937964T2 (de)
DK (1) DK1129064T3 (de)
ES (1) ES2296419T3 (de)
NZ (1) NZ512244A (de)
PT (1) PT1129064E (de)
WO (1) WO2000027795A1 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
DK1129064T3 (da) * 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
GB9914085D0 (en) * 1999-06-16 1999-08-18 Smithkline Beecham Plc New use
GB9914045D0 (en) * 1999-06-16 1999-08-18 Smithkline Beecham Plc Novel compounds
US7294511B2 (en) 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US6741357B2 (en) * 2001-08-14 2004-05-25 Seagate Technology Llc Quadrature phase shift interferometer with unwrapping of phase
AU2003217028A1 (en) * 2002-03-27 2003-10-13 Cambridge University Technical Services Ltd Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
EP2338478B1 (de) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Verfahren zur Herstellung von Liposomen
AU2003268478A1 (en) * 2002-10-16 2004-05-25 Neopharm, Inc. Cardiolipin molecules and method of synthesis
US7531693B2 (en) 2003-05-22 2009-05-12 Molecular Transfer, Inc. Lipids for transfection of nucleic acids
NZ581166A (en) 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
WO2005039642A1 (en) * 2003-10-24 2005-05-06 University Of Saskatchewan Dna delivery with gemini cationic surfactants
US7691607B2 (en) * 2004-02-09 2010-04-06 The Regents Of The University Of California Expression system of NELL peptide
WO2005121348A1 (en) * 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
GB0413613D0 (en) * 2004-06-17 2004-07-21 Univ London Small molecule carriers
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
US20070117179A1 (en) * 2005-09-27 2007-05-24 Invitrogen Corporation In vitro protein synthesis systems for membrane proteins that include adolipoproteins and phospholipid-adolipoprotein particles
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
EP2395012B8 (de) 2005-11-02 2018-06-06 Arbutus Biopharma Corporation Modifizierte siRNA-Moleküle und Verwendungen davon
WO2007053235A1 (en) * 2005-11-04 2007-05-10 Sachem, Inc. Cation-exchange displacement chromatography process and cationic organic compounds for use as displacer compounds in cation-exchange displacement chromatography process
DE102006008701A1 (de) * 2006-02-23 2007-08-30 Qiagen Gmbh Ein Verfahren zur Herstellung einer transformierten Zelle
JP5364574B2 (ja) 2006-05-05 2013-12-11 モレキュラー、トランスファー、インコーポレイテッド 真核細胞のトランスフェクションのための新規試薬
JP5407862B2 (ja) * 2006-10-04 2014-02-05 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） ｓｉＲＮＡおよび脂質性４，５−二置換２−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
WO2008106660A2 (en) * 2007-03-01 2008-09-04 Invitrogen Corporation Isolated phospholipid-protein particles
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
GB0720486D0 (en) * 2007-10-19 2007-11-28 Univ Edinburgh Cationic lipids
UA97559C2 (uk) 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
EP2238251B1 (de) * 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing der polo-like-kinase-expression unter verwendung von interferenz-rna
EP3100718B1 (de) * 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
US8722082B2 (en) 2008-11-10 2014-05-13 Tekmira Pharmaceuticals Corporation Lipids and compositions for the delivery of therapeutics
EP4241767A3 (de) 2008-11-10 2023-11-01 Arbutus Biopharma Corporation Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
WO2010083615A1 (en) 2009-01-26 2010-07-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
CA2753703A1 (en) 2009-03-04 2010-09-10 Hirofumi Takeuchi Nucleic acid complex and nucleic acid-delivering composition
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
EP2449114B9 (de) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Neue lipidformulierungen zur abgabe von therapiemitteln in feste tumore
US8716464B2 (en) * 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
US8455455B1 (en) 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
CN113214102A (zh) 2010-11-15 2021-08-06 生命技术公司 含胺的转染试剂及其制备和使用方法
NZ703649A (en) 2010-12-06 2016-08-26 Penn State Res Found Compositions and methods relating to proliferative diseases
US8695618B2 (en) 2010-12-22 2014-04-15 Carnegie Mellon University 3D chemical pattern control in 2D fluidics devices
WO2012142622A1 (en) 2011-04-15 2012-10-18 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
CN102319550B (zh) * 2011-07-08 2014-01-22 中国林业科学研究院林产化学工业研究所 一种低浓度粘弹表面活性剂溶液及其制备方法
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
CN103930398B (zh) * 2011-11-18 2016-08-24 日油株式会社 具有改进的细胞内动力学的阳离子脂质
EP2791160B1 (de) 2011-12-16 2022-03-02 ModernaTX, Inc. Modifizierte mrna zusammensetzungen
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
JP6473079B2 (ja) 2012-05-02 2019-02-20 ライフ テクノロジーズ コーポレーション 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
US9758606B2 (en) 2012-07-31 2017-09-12 The Trustees Of Columbia University In The City Of New York Cyclopropenium polymers and methods for making the same
CA2885223C (en) * 2012-10-08 2021-04-13 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
WO2014070687A2 (en) 2012-10-29 2014-05-08 Molecular Transfer, Inc. Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells
ITRM20130054A1 (it) * 2013-01-30 2014-07-31 Paolo Gresele Piastrine trasfettate con materiale genetico esogeno e microparticelle derivate da dette piastrine trasfettate, metodo per la loro preparazione e loro usi.
WO2014142995A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
CA2905649A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
WO2014207231A1 (en) * 2013-06-28 2014-12-31 Ethris Gmbh Compositions for introducing rna into cells
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) * 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
EP3066201B1 (de) 2013-11-07 2018-03-07 Editas Medicine, Inc. Crispr-assoziierte verfahren und zusammensetzungen mit regelnden grnas
JP6912887B2 (ja) 2013-12-12 2021-08-04 ライフ テクノロジーズ コーポレーション トランスフェクションの強化のための膜透過性ペプチドならびにそれらを使用する組成物及び方法
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
CN106572974B (zh) 2014-07-15 2021-04-23 生命技术公司 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
RU2718590C2 (ru) * 2014-11-10 2020-04-08 Этрис Гмбх Индукция остеогенеза путем внедрения рнк, кодирующей костный морфогенетический белок (кмб)
WO2016112963A1 (en) 2015-01-13 2016-07-21 Riboxx Gmbh Delivery of biomolecules into cells
US10385030B2 (en) 2015-01-30 2019-08-20 Nof Corporation Cationic lipid
JP7199809B2 (ja) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド 核酸製品及びその投与方法
CN104876831B (zh) * 2015-04-03 2017-05-17 苏州圣诺生物医药技术有限公司 脂质修饰精胺衍生物及利用该衍生物制备的脂质体
CN107922961A (zh) 2015-07-13 2018-04-17 生命技术公司 用于cho细胞中经改善的瞬时蛋白质表达的系统和方法
EP3341027B1 (de) * 2015-08-28 2024-03-06 Molecular Transfer, Inc. Transfektionskomplexe und verfahren zur verwendung davon
EP3141582B1 (de) * 2015-09-10 2018-06-13 Karlsruher Institut für Technologie Synthese und verwendung von polyalkylaminen
JP2018532404A (ja) 2015-10-14 2018-11-08 ライフ テクノロジーズ コーポレーション リボ核タンパク質トランスフェクション薬剤
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
CN108779074A (zh) 2016-03-01 2018-11-09 分子传递有限公司 植物病毒移动蛋白和其使用方法
IL308426A (en) 2016-08-03 2024-01-01 Harvard College Adenosine nuclear base editors and their uses
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
IL264439B1 (en) 2016-08-17 2024-04-01 Factor Bioscience Inc A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3518981A4 (de) 2016-10-03 2020-06-10 President and Fellows of Harvard College Abgabe von therapeutischen rnas über arrdc1-vermittelte mikrovesikel
AU2017342543A1 (en) 2016-10-14 2019-05-02 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
JP7191388B2 (ja) 2017-03-23 2022-12-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸によってプログラム可能なｄｎａ結合蛋白質を含む核酸塩基編集因子
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (de) 2017-07-28 2020-06-03 President and Fellows of Harvard College Verfahren und zusammensetzungen zur entwicklung von basiseditoren unter verwendung von phagenunterstützter kontinuierlicher entwicklung (pace)
JP7282379B2 (ja) 2017-08-22 2023-05-29 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
JP7379325B2 (ja) * 2017-08-31 2023-11-14 ライフ テクノロジーズ コーポレイション 組織特異的送達用のカチオン性脂質組成物
EP3697906A1 (de) 2017-10-16 2020-08-26 The Broad Institute, Inc. Verwendungen von adenosinbasiseditoren
AU2018374219C1 (en) 2017-12-01 2023-05-11 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
WO2019105419A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7436030B2 (ja) * 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 複合体及びその調製方法と使用
WO2019176079A1 (ja) * 2018-03-16 2019-09-19 株式会社 東芝 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット
EP3778572A4 (de) 2018-03-27 2021-12-22 NOF Corporation Neues kationisches lipid mit verbesserter intrazellulärer dynamik
WO2019210394A1 (en) 2018-04-29 2019-11-07 Precision Nanosystems Inc. Compositions for transfecting resistant cell types
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
CN111655849A (zh) 2018-08-21 2020-09-11 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
EP3842412B1 (de) * 2018-08-21 2024-04-24 Kabushiki Kaisha Toshiba Biologisch abbaubare lipide zur freisetzung von wirkstoffen in tumorzellen umfassend zwei oder mehrere tertiäre aminogruppen
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
PT3646854T (pt) 2018-10-30 2022-09-27 Polyplus Transfection Composições para transfecção de mrna numa célula e suas aplicações
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
EP4223886A3 (de) 2019-04-16 2023-09-13 Genfit Zusammensetzungen und verfahren zur stabilisierung von mikro-rna
US20220175723A1 (en) 2019-04-22 2022-06-09 The Penn State Research Foundation Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer
CN114450265A (zh) * 2019-07-03 2022-05-06 菲克特生物科学股份有限公司 阳离子脂质及其用途
JP2021016371A (ja) * 2019-07-23 2021-02-15 株式会社東芝 Ｃａｒ−ｔ細胞の製造方法、核酸導入キャリア及びキット
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
KR20220054316A (ko) * 2019-08-05 2022-05-02 뽈리쁠뤼스-트랑스펙씨옹 (쏘시에떼 아노님) 양이온성 중합체에 그래프트된 트리아졸 화합물을 포함하는, 핵산 분자를 세포 내로 형질감염시키기 위한 조성물, 및 이의 적용
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
EP3929295A1 (de) 2020-06-26 2021-12-29 Universitat Pompeu Fabra Künstliche rnas zur modulation von rna-fragmenten
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
EP4015634A1 (de) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna und zusammensetzungen zur prophylaktischen und therapeutischen behandlung von viruskrankheiten
WO2023018990A2 (en) * 2021-08-12 2023-02-16 Life Technologies Corporation Lipids for nucleic acid delivery
US20230279433A1 (en) 2021-12-15 2023-09-07 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
US20230392188A1 (en) 2022-06-02 2023-12-07 Perkinelmer Health Sciences, Inc. Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids
CN116444395A (zh) * 2022-06-27 2023-07-18 上海云沂生物医药科技有限公司 一种氨基脂质、其合成方法、颗粒及用途
WO2024006937A1 (en) 2022-06-30 2024-01-04 Life Technologies Corporation Lipid compositions for in vivo delivery

Family Cites Families (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554307A (en) * 1896-02-11 Controller for electric motors
US204672A (en) * 1878-06-11 Improvement in lubricators
US2046720A (en) * 1933-06-09 1936-07-07 Girdler Corp Nu-hydroxy-aminoalkyl substituted alkylene diamines
US2654785A (en) 1949-02-15 1953-10-06 Ciba Pharm Prod Inc Quaternated aza-pentane amines
US2695314A (en) 1951-08-25 1954-11-23 Monsanto Chemicals Hydroxyethylated-n-keryl alkylenediamines
US2901461A (en) 1955-05-05 1959-08-25 Union Carbide Corp Curable glycidyl polyether-polyamine compositions
US2933529A (en) * 1956-01-09 1960-04-19 Rohm & Haas Symmetrical diquaternary ammonium compounds
FR1146332A (fr) * 1956-03-29 1957-11-08 Produits de nettoyage de la chevelure et sels de diamines bitertiaires entrant dans la composition de ces produits
US2867665A (en) 1956-07-09 1959-01-06 Searle & Co Alkylenebis [trialkylphosphonium halides] and processes for the manufacture thereof
GB892413A (en) 1957-07-15 1962-03-28 Nat Res Dev Poly-onium neuromuscular blocking agents
NL109859C (de) * 1957-09-27
US3152188A (en) 1960-11-15 1964-10-06 Nalco Chemical Co Nu-substituted polyalkylene polyamines having 2-hydroxyethyl and mono-secondary-hydroxyl hydrocarbon substituents
US3152168A (en) 1961-09-05 1964-10-06 Monsanto Co Haloalkyl pentahalophenyl carbonates
US3324182A (en) 1962-12-26 1967-06-06 Monsanto Res Corp Penta-alkyldialkylenetriamines
US3369905A (en) 1963-03-19 1968-02-20 Eastman Kodak Co Photographic silver halide emulsions containing polyamine sensitizing agents
DE1617126C3 (de) * 1967-03-01 1975-06-19 Henkel & Cie Gmbh, 4000 Duesseldorf Maschinenwaschmittel
IT956228B (it) 1972-04-15 1973-10-10 Snia Viscosa Metodo ed additivi per conferire proprieta antistatiche a composi zioni poliammidiche e prodotti poliammidici ottenuti secondo tale metodo e con l impiego di tali additivi
DE2624527A1 (de) 1976-06-01 1977-12-22 Bayer Ag Verfahren zur herstellung von polyurethanen
CH646742A5 (de) * 1977-07-06 1984-12-14 Procter & Gamble Konzentrierte fluessige weichmacherzusammensetzung.
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JPS59186943A (ja) * 1983-04-07 1984-10-23 Toyo Soda Mfg Co Ltd ビス〔β−（Ｎ，Ｎ−ジメチルアミノ）エチル〕エ−テルの製造法
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
GB8413911D0 (en) * 1984-05-31 1984-07-04 British Petroleum Co Plc Encapsulating organic material
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
NZ214716A (en) 1985-01-07 1989-04-26 Syntex Inc 1,2-dialkoxy-omega-trialkylammonium cationic surfactants
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4767699A (en) 1985-05-02 1988-08-30 Allied Corporation Diagnostic reagent, kit and method employing polynucleotide displacement, separation, enzymatic cleavage and adenosine phosphate detection
EP0238645A1 (de) 1985-10-03 1987-09-30 Biotechnology Research Partners, Ltd. Neue arzneimittel verabreichende systeme auf der basis von lipoproteinen
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4812449A (en) 1986-07-03 1989-03-14 Scripps Clinic And Research Foundation In situ active compound assembly
JP2561478B2 (ja) 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US5560929A (en) 1986-08-18 1996-10-01 The Dow Chemical Company Structured copolymers and their use as absorbents, gels and carriers of metal ions
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5079352A (en) 1986-08-22 1992-01-07 Cetus Corporation Purified thermostable enzyme
US5374553A (en) 1986-08-22 1994-12-20 Hoffmann-La Roche Inc. DNA encoding a thermostable nucleic acid polymerase enzyme from thermotoga maritima
US4962022A (en) 1986-09-22 1990-10-09 Becton Dickinson And Company Storage and use of liposomes
US5342945A (en) * 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US5091576A (en) 1986-12-02 1992-02-25 University Of Florida Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4776288A (en) 1987-07-31 1988-10-11 Metallgesellschaft Aktiengesellschaft Method for improving solids distribution in a circulating fluidized bed system
US5244797B1 (en) 1988-01-13 1998-08-25 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking rnase h activity
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5498523A (en) 1988-07-12 1996-03-12 President And Fellows Of Harvard College DNA sequencing with pyrophosphatase
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5206036A (en) * 1988-10-19 1993-04-27 E. I. Du Pont De Nemours And Company Apparatus for shaping fiber reinforced resin matrix materials
WO1991008191A1 (en) 1989-11-14 1991-06-13 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and method of use thereof
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
AU5192190A (en) 1989-02-24 1990-09-26 City Of Hope Heterologous block oligomers
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
ATE277193T1 (de) 1989-03-21 2004-10-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5165925A (en) 1989-05-02 1992-11-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Vaccine for immunizing fish against infectious pancreatic necrosis virus
US5198423A (en) 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5514787A (en) 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
US5047342A (en) 1989-08-10 1991-09-10 Life Technologies, Inc. Cloning and expression of T5 DNA polymerase
US5270179A (en) 1989-08-10 1993-12-14 Life Technologies, Inc. Cloning and expression of T5 DNA polymerase reduced in 3'- to-5' exonuclease activity
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
BE1003510A5 (fr) 1989-10-09 1992-04-07 Fabricom Air Conditioning Sa Composition desinfectante et procede de desinfection.
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5583198A (en) * 1989-12-22 1996-12-10 Commonwealth Scientific And Industrial Research Organization Amino acids, peptides or derivatives thereof coupled to fats
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5506212A (en) 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US4967008A (en) 1990-01-12 1990-10-30 Sherex Chemical Company, Inc. Polyamines and their preparation
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1993008130A1 (fr) 1990-05-02 1993-04-29 Laboratoires Mcs-Pharma S.A. Procede de desinfection de l'eau et compositions pour sa mise en ×uvre
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5773527A (en) * 1990-08-27 1998-06-30 Dendritech, Inc. Non-crosslinked, polybranched polymers
US5631329A (en) 1990-08-27 1997-05-20 Dendritech, Inc. Process for producing hyper-comb-branched polymers
AU628690B2 (en) * 1990-08-27 1992-09-17 Pratley Investments (Proprietary) Limited Adhesive primer
US5187085A (en) 1990-09-28 1993-02-16 Applied Biosystems, Inc. Nucleic acid sequence analysis with nucleoside-5'-o-(1-thiotriphosphates)
DK0550687T3 (da) 1990-09-28 1999-12-13 Hoffmann La Roche 5' til 3'-exonukleasemutationer af termostabile DNA-polymeraser
EP0553264A4 (en) 1990-10-05 1994-07-13 Wayne M Barnes Thermostable dna polymerase
US5186923A (en) 1990-10-10 1993-02-16 Brigham And Womens Hospital Enhancement of cellular accumulation of lipophilic cationic organometallic compounds by reduction of intramembrane potential
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
DE4102497C1 (de) 1991-01-29 1992-05-07 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5977306A (en) * 1991-02-12 1999-11-02 Heska Corporation Parasitic helminth P39 proteins, and uses thereof
DE4104186A1 (de) 1991-02-12 1992-08-13 Genentech Inc Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
US5328984A (en) 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
CA2102804A1 (en) 1991-05-10 1992-11-11 Sudhir Agrawal 3'-end blocked oligonucleotides
EP0603187A4 (en) 1991-05-31 1995-08-30 Us Health Human lactoferrin.
WO1992022635A1 (en) 1991-06-05 1992-12-23 University Of Connecticut Targeted delivery of genes encoding secretory proteins
CA2066540C (en) * 1991-06-13 1998-01-20 Edwin A. Kelley Multiple user digital receiving apparatus and method with time division multiplexing
US6251390B1 (en) 1991-06-17 2001-06-26 Cornell Research Foundation, Inc. Purified chitinases and use thereof
JP2902165B2 (ja) * 1991-07-12 1999-06-07 三菱鉛筆株式会社 アルコール性マーキングペンインキ組成物
WO1993003709A1 (en) 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5196135A (en) * 1991-10-07 1993-03-23 Isp Investments Inc. Antimicrobial, low toxicity, blend composition of bis-quaternary ammonium compounds
US5242684A (en) * 1991-10-25 1993-09-07 Isp Investments Inc. Antimicrobial, low toxicity, non-irritating composition comprising a blend of bis-quaternary ammonium compounds coprecipitated with a copolymer of vinylpyrrolidone and an acrylamido or vinyl quaternary ammonium monomer
DE4133484A1 (de) 1991-10-09 1993-04-15 Teves Gmbh Alfred Bremsanlage mit blockierschutz und antriebsschlupfregelung
JP2849517B2 (ja) * 1991-10-16 1999-01-20 株式会社バイオマテリアル研究所 新規生理活性物質エピモルフィン、それをコードする遺伝子及びエピモルフィンに対する抗体
DE4139001A1 (de) 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur einschleusung von nukleinsaeuren in zellen
US5338837A (en) 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
ES2159291T3 (es) 1992-02-24 2001-10-01 Genelabs Tech Inc Metodo y analisis de htlv-i/htlv-ii.
US5459030A (en) 1992-03-02 1995-10-17 Steritech, Inc. Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5543507A (en) 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
EP1236473A3 (de) 1992-04-03 2003-01-15 The Regents Of The University Of California Selbst zusammenbaubares system zur verabreichung von polynukleotiden
CA2094341A1 (en) 1992-04-28 1993-10-29 Carl W. Porter Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
CA2140669A1 (en) 1992-07-20 1994-02-03 David Ecker Pseudo-half-knot rna formation by hybridization of antisense oligonucleotides to target rna's secondary structure
EP0652890B1 (de) 1992-07-27 1998-01-14 HYBRIDON, Inc. Oligonukleotid alkylphosphonothiate
JPH08500386A (ja) * 1992-08-20 1996-01-16 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 架橋ポリマーアンモニウム塩
IL106760A (en) 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5414074A (en) 1992-09-25 1995-05-09 University Of Michigan Synthesis of C-glycosylated compounds with the use of a mild, iodine-catalyzed reaction
WO1994007906A1 (en) * 1992-10-01 1994-04-14 Board Of Regents, The University Of Texas System Epidermal surface antigen and uses thereof
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
CA2146364A1 (en) 1992-10-05 1994-04-14 Sudhir Agrawal Therapeutic anti-hiv oligonucleotide and pharmaceutical
US5266106A (en) 1992-10-22 1993-11-30 Xerox Corporation Ink compositions with dendrimer grafts
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
JPH08501799A (ja) 1992-12-21 1996-02-27 タノックス バイオシステムズ インコーポレイテッド アレルゲン特異的ＩｇＡモノクローナル抗体及びアレルギー治療のための関連物質
US5350672A (en) 1993-01-22 1994-09-27 Kansas State University Research Foundation Specific DNA primers and method to use same detect Eperythrozoon suis
DE69400208T2 (de) 1993-01-25 1996-11-28 Hybridon Inc Olionukleotidalkylphosphonate und -phosphonothioate
US5532142A (en) 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5436149A (en) 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
US6103492A (en) 1993-03-08 2000-08-15 Indiana University Polynucleotide encoding mu opioid receptor
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
AU6568594A (en) 1993-04-14 1994-11-08 Boehringer Mannheim Gmbh Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
EP1300156A3 (de) * 1993-05-18 2003-05-07 The Ohio State University Research Foundation Impfstoff gegen Mittelohrentzündung
JPH09500013A (ja) * 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
AU7097494A (en) * 1993-06-01 1994-12-20 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
ES2114692T3 (es) 1993-06-09 1998-06-01 Gamera Bioscience Corp Reaccion en ciclos magneticos.
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
DE69433519T2 (de) 1993-07-14 2004-11-11 The Regents Of The University Of California, Oakland Sich selbst zusammensetzendes polynukleotid-abgabesystem, das dendrimer-polykationen enthält
US5500356A (en) 1993-08-10 1996-03-19 Life Technologies, Inc. Method of nucleic acid sequence selection
US5510239A (en) 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
DE4340467C2 (de) 1993-11-27 2002-03-14 Bosch Gmbh Robert Mit Fremdkraft arbeitende hydraulische Fahrzeugbremsanlage
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5556772A (en) 1993-12-08 1996-09-17 Stratagene Polymerase compositions and uses thereof
US5801270A (en) 1993-12-15 1998-09-01 Kao Corporation Amine derivative and detergent composition containing the same
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5484702A (en) 1994-01-27 1996-01-16 Research Foundation Of The State University Of New York At Buffalo Method for preselecting recombinant clones containing a specific nucleic acid sequence and subsequent transformation with preselected clones
US5759805A (en) * 1994-01-28 1998-06-02 Targeted Genetics Corporation And Immunex CD69 transcriptional regulatory elements
JP3616394B2 (ja) 1994-01-31 2005-02-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｄｎａ配列決定のアーティファクトの除去のための方法
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5512462A (en) 1994-02-25 1996-04-30 Hoffmann-La Roche Inc. Methods and reagents for the polymerase chain reaction amplification of long DNA sequences
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
DE4411594C1 (de) 1994-03-30 1995-12-14 Deutsches Rheumaforschungszent Testkit zur Bestimmung von Histokompatibilitäts-Antigenen
DE4411588C1 (de) 1994-03-30 1995-09-28 Deutsches Rheuma Forschungszen Puffer für DNA- und RNA-Polymerase-Reaktionen
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5510476A (en) 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
AUPM747694A0 (en) 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
DE4432485A1 (de) 1994-09-13 1996-03-14 Nobis Labordiagnostika Gmbh Schnelltest zur Differenzierung von Erythrozytenmerkmalen
US5892071A (en) * 1994-09-30 1999-04-06 The Reagents Of The University Of California Cationic transport reagents
US5527928A (en) * 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
DE69527206T2 (de) * 1994-09-30 2003-02-27 Inex Pharmaceuticals Corp Mittel zum einbringen polyanionischer materialien in zellen
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5912155A (en) 1994-09-30 1999-06-15 Life Technologies, Inc. Cloned DNA polymerases from Thermotoga neapolitana
US5614365A (en) 1994-10-17 1997-03-25 President & Fellow Of Harvard College DNA polymerase having modified nucleotide binding site for DNA sequencing
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5587441A (en) 1994-11-08 1996-12-24 Cornell Research Foundation, Inc. Hyperbranched polymers from AB monomers
EP0792166B1 (de) 1994-11-17 2011-03-23 ICH Productions Limited Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5635487A (en) 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
ATE194391T1 (de) * 1995-01-19 2000-07-15 Gen Probe Inc Amplifikationsoligonukleotide und sonden für borrelia, die mit lyme kranheit assoziiert sind
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
JPH11502818A (ja) 1995-03-23 1999-03-09 ハイブライドン インコーポレイテッド チオノトリエステル修飾アンチセンスオリゴデオキシヌクレオチドホスホロチオエート
WO1996031549A1 (de) 1995-04-07 1996-10-10 Mueller Egbert Dendrimere pfropfpolymerisate
US6372427B1 (en) 1995-04-12 2002-04-16 Hybridon, Inc. Cooperative oligonucleotides
US5804376A (en) * 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
WO1996035706A1 (en) 1995-05-11 1996-11-14 Hybridon, Inc. Pyrimidine targeting hairpin triplex-forming oligonucleotides
US5693773A (en) * 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
EP1489184A1 (de) * 1995-06-07 2004-12-22 Inex Pharmaceutical Corp. Herstellung von Lipid-nukleinsäure Partikeln duch ein hydrophobische Lipid-nukleinsäuree Komplexe Zwischenprodukt und zur Verwendung in der Gentransfer
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736392A (en) 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
DE19523516C1 (de) 1995-06-30 1996-10-31 Asta Medica Ag Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen
CA2227786A1 (en) 1995-07-28 1997-02-13 Marie Curie Cancer Care Transport proteins and their uses
EP0871775A4 (de) 1995-09-08 2002-07-31 Life Technologies Inc Klonierte dna-polymerasen von thermotoga und mutanten davon
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5869715A (en) * 1995-09-27 1999-02-09 The Reagents Of The University Of California Polyfunctional cationic cytofectins
US6086913A (en) 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US5595096A (en) 1996-01-04 1997-01-21 Coffman; George L. English-metric wrench socket or drive
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US5962533A (en) * 1996-02-06 1999-10-05 University Of Florida Research Foundation, Inc. Hydroxy polyamines
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
WO1997042819A1 (en) * 1996-05-13 1997-11-20 Alberto Haces Cationic lipids for transfection of negatively charged or neutral molecules into living cells
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5871929A (en) * 1996-07-23 1999-02-16 Barnes; Wayne M. Suppression of pyrophosphorolysis in DNA sequencing and in other applications involving DNA replication
US6013488A (en) 1996-07-25 2000-01-11 The Institute Of Physical And Chemical Research Method for reverse transcription
EP0942917B1 (de) 1996-08-14 2015-02-25 Life Technologies Corporation Verwendung von stabile zubereitungen in nukleinsäureamplifikation und sequenzierung verfahren
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
CA2217550A1 (en) * 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
CA2270396C (en) * 1996-11-04 2008-03-11 Qiagen Gmbh Cationic reagents for transfection
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
FR2760193B1 (fr) * 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
WO1998040499A1 (en) * 1997-03-10 1998-09-17 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purposes
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
WO1998047912A1 (en) 1997-04-22 1998-10-29 Life Technologies, Inc. Methods for the production of aslv reverse transcriptases composed of multiple subunits
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
WO1999002190A1 (en) 1997-07-11 1999-01-21 Genzyme Corporation Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy
EP0998577B1 (de) 1997-07-24 2004-10-27 Perseptive Biosystems, Inc. Konjugate von transportpeptiden und nukleinsäureanaloga und deren verwendung
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
GB9723825D0 (en) 1997-11-11 1998-01-07 Actinova Ltd Nuclear targeting by means of bacterial proteins
GB9726073D0 (en) * 1997-12-09 1998-02-04 Smithkline Beecham Plc Novel compounds
US6343516B1 (en) * 1998-01-16 2002-02-05 Texaco Inc. Multiphase flow sampling using an autotraversing sample probe
IL123256A0 (en) 1998-02-10 1998-09-24 Yeda Res & Dev Methods for dna amplification and sequencing
US6787305B1 (en) 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
JP2002511446A (ja) 1998-04-08 2002-04-16 セルテック・セラピューティクス・リミテッド 脂 質
AU5588199A (en) 1998-08-27 2000-03-21 Alberto Haces Novel polycationic lipids
AT409631B (de) * 1998-10-28 2002-09-25 Solutia Austria Gmbh Ionisch oder nichtionisch stabilisierte epoxidaddukte als wasserverdünnbare basisharze für 2 k-isocyanat systeme
US6333433B1 (en) * 1998-11-09 2001-12-25 Council Of Scientific Industrial Research Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkl group for intracellular delivery of biologically active molecules
DK1129064T3 (da) 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
US6355199B1 (en) * 1999-02-12 2002-03-12 St. Assembly Test Services Pte Ltd Method of molding flexible circuit with molded stiffener
US7074556B2 (en) 1999-03-02 2006-07-11 Invitrogen Corporation cDNA synthesis improvements
US6773920B1 (en) * 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
CA2368998A1 (en) 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
EP1187807B1 (de) 1999-04-26 2007-07-25 Celltech R&D Limited Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen
US6830902B1 (en) 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
CA2405768A1 (en) * 2000-04-12 2001-10-25 Dana-Farber Cancer Institute Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
EP1337664A4 (de) * 2000-10-27 2005-01-19 Invitrogen Corp Verfahren zur einführung von antisense-oligonukleotiden in eukaryontische zellen
EP1275735A1 (de) 2001-07-11 2003-01-15 Roche Diagnostics GmbH Zusammensetzung und Methode zur 'Hot start' Nukleinsäureamplifizierung
US6766777B2 (en) * 2002-06-14 2004-07-27 Borgwarner, Inc. Method to ensure robust operation of a pin lock in a vane style cam phaser
WO2004063342A2 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
US7531693B2 (en) * 2003-05-22 2009-05-12 Molecular Transfer, Inc. Lipids for transfection of nucleic acids
DE102006033091A1 (de) 2006-07-14 2008-01-24 Bayer Cropscience Ag Verfahren zum Herstellen von in 1'-Stellung unverzweigten Alkenylnitrobenzolderivaten
GB2466305B (en) 2008-12-19 2015-06-03 Autoflame Eng Ltd Burner installation

Also Published As

Publication number Publication date
NZ512244A (en) 2003-12-19
US20070202600A1 (en) 2007-08-30
CA2350882C (en) 2011-02-22
DK1129064T3 (da) 2008-04-28
EP1129064A1 (de) 2001-09-05
US7479573B2 (en) 2009-01-20
US8158827B2 (en) 2012-04-17
US20150190522A1 (en) 2015-07-09
AU772847B2 (en) 2004-05-06
JP2002529439A (ja) 2002-09-10
US20050164391A1 (en) 2005-07-28
WO2000027795A1 (en) 2000-05-18
US20050164971A1 (en) 2005-07-28
US7915450B2 (en) 2011-03-29
EP2298728A1 (de) 2011-03-23
US9358300B2 (en) 2016-06-07
US20050164972A1 (en) 2005-07-28
US7173154B2 (en) 2007-02-06
PT1129064E (pt) 2008-01-31
CY1107895T1 (el) 2013-09-04
US8785200B2 (en) 2014-07-22
US7470817B2 (en) 2008-12-30
US20070202598A1 (en) 2007-08-30
JP2011121966A (ja) 2011-06-23
ES2296419T3 (es) 2008-04-16
US7323594B2 (en) 2008-01-29
US20050124069A1 (en) 2005-06-09
AU1477600A (en) 2000-05-29
US7166745B1 (en) 2007-01-23
CA2350882A1 (en) 2000-05-18
US20050260597A1 (en) 2005-11-24
US20090143583A1 (en) 2009-06-04
EP1129064B1 (de) 2008-01-09
US7145039B2 (en) 2006-12-05
DE69937964T2 (de) 2009-01-02
EP1829856A3 (de) 2009-02-25
ATE383331T1 (de) 2008-01-15
EP1829856A2 (de) 2007-09-05
US7601872B2 (en) 2009-10-13
US20100159593A1 (en) 2010-06-24
US20120238747A1 (en) 2012-09-20
JP4854853B2 (ja) 2012-01-18

Similar Documents

Publication Publication Date Title
DE69937964D1 (de) Transportreagentien
DK1020462T3 (da) Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens
DE69905906D1 (de) Kombination von zwei oder mehreren wirkstoffen unter verwendung von mikrokapsel-formulierungen
DE69829086D1 (de) Phiole für Implantat
DE59802860D1 (de) Desinfektionsmittel
DE69634670D1 (de) Aktives anodenmaterial und nichtwässrige sekundärbatterie
EE200000283A (et) Keemilised ühendid
EE200000284A (et) Keemilised ühendid
ID22878A (id) Komposisi aktif secara terapi
DK1006792T3 (da) Landbrugskemisk sammensætning
DE69815524D1 (de) Haftende mikrokapseln enthaltend biologisch aktive substanzen
FI972330A (fi) Biasjänniteohjattuja rinnakkaisia aktiivikomponentteja
DE69812371D1 (de) Phenyllacrylsäurederivate enthaltende fungizide kombinationen
NO20016147L (no) Biologiske aktive materialer
EE9800193A (et) Bioloogilise toimega bensotiasolooni etaanamiinid
DE69829236D1 (de) Zusammensetzungen enthaltendes biologisch aktives Silizium
DE69917070D1 (de) Aktive sauerstoffentfernende verpackung
DE69838479D1 (de) Segmentierte polyurethan biomaterialien enthaltende medizinische geräte
EE9900442A (et) Bioloogiliselt aktiivne materjal
KR940022660U (ko) 유기물 발효기용 탈취장치
DE9310990U1 (de) Abdeckung für zwangsbelüftete biologisch aktive Haufwerke
FI974008A (fi) Asuttava liikenneväline
DE29718555U1 (de) Gewebsproben-Transportbox
FI921175A0 (fi) Biologiskt aktiv kemisk foerening.
DE69820845D1 (de) Baukastenträger

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LIFE TECHNOLOGIES CORP. (N.D.GES.D. STAATES DE, US